Terumo Aortic’s RelayPro Thoracic Stent Graft System Introduced Commercially in United States

September 16, 2021—Terumo Aortic announced the first commercial implants in the United States of its RelayPro thoracic stent graft system, which was recently approved by the FDA for treatment of patients with fusiform and saccular aneurysms and penetrating atherosclerotic ulcers in the descending thoracic aorta. The device received European CE Mark approval in 2017.

The implantation procedures were performed by Venkatesh G. Ramaiah, MD, Chief of Vascular and Endovascular Surgery, Honor Health Network, in Scottsdale, Arizona, and Wilson Y. Szeto, MD, Chief of Cardiovascular Surgery, Penn Presbyterian University of Pennsylvania Health System, in Philadelphia, Pennsylvania. Drs. Ramaiah and Szeto are Conational Principal Investigators of the pivotal RelayPro aneurysm study.

“The low-profile delivery system is designed to accommodate patients with smaller access vessels,” commented Dr. Ramaiah in Terumo Aortic’s press release. “The platform utilizes the same stent design, materials, and dual-sheath technology of the proven RelayPlus system, delivering the accuracy, control, and confidence of RelayPlus without compromising device integrity and durability.”

Dr. Szeto added, “RelayPro is the only lower-profile device with a non–bare-stent design available in the United States to treat aneurysms and penetrating atherosclerotic ulcers. The unique technology incorporated into the delivery system is integral to securing optimal wall apposition and allows for the effective treatment of patients with thoracic aneurysms.”